$10.78
5.02% yesterday
Nasdaq, Aug 12, 10:16 pm CET
ISIN
US0327973006
Symbol
AVXL

Anavex Life Sciences Corp. Stock price

$10.78
-0.70 6.10% 1M
+2.08 23.91% 6M
+0.04 0.37% YTD
+4.62 75.00% 1Y
-0.87 7.47% 3Y
+6.78 169.50% 5Y
+5.66 110.55% 10Y
+10.71 16,061.92% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.57 5.02%
ISIN
US0327973006
Symbol
AVXL
Industry

Key metrics

Basic
Market capitalization
$969.5m
Enterprise Value
$853.7m
Net debt
positive
Cash
$115.8m
Shares outstanding
85.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.7
Financial Health
Equity Ratio
88.7%
Return on Equity
-35.8%
ROCE
-55.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $148.9m
EBIT
$-55.2m | $-52.9m
Net Income
$-47.1m | $-48.5m
Free Cash Flow
$-29.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-10.4% | -0.1%
Net Income
-16.1% | -12.7%
Free Cash Flow
8.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.3
Short interest
30.4%
Employees
42
Rev per Employee
$0.0
Show more

Is Anavex Life Sciences Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Anavex Life Sciences Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Anavex Life Sciences Corp. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Anavex Life Sciences Corp. forecast:

Buy
89%
Hold
11%

Financial data from Anavex Life Sciences Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
2% 2%
-
- Research and Development Expense 44 44
13% 13%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -55 -55
10% 10%
-
Net Profit -47 -47
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anavex Life Sciences Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anavex Life Sciences Corp. Stock News

Neutral
Seeking Alpha
about 10 hours ago
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q3 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Christopher U. Missling - President, CEO, Secretary & Director Clint Tomlinson - VP of Corporate Sandra Boenisch - Principal Financial Officer & Treasurer Conference Call Participants Jesse Silveira - Unidentified Company Soumit Roy - JonesTrading Institutional Services, LL...
Neutral
GlobeNewsWire
about 13 hours ago
Company to host a webcast today at 8:30 a.m. Eastern Time
Neutral
GlobeNewsWire
8 days ago
Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET
More Anavex Life Sciences Corp. News

Company Profile

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Head office United States
CEO Christopher Missling
Employees 42
Founded 2004
Website www.anavex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today